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Antineoplastic therapy has been associated with pain syndrome development characterized by acute and chronic pain. The
chemotherapeutic agent dacarbazine, used mainly to treat metastatic melanoma, is reported to cause painful symptoms,
compromising patient quality of life. Evidence has proposed that transient receptor potential ankyrin 1 (TRPA1) plays a critical
role in chemotherapy-induced pain syndrome. Here, we investigated whether dacarbazine causes painful hypersensitivity in
naive or melanoma-bearing mice and the involvement of TRPA1 in these models. Mouse dorsal root ganglion (DRG) neurons
and human TRPA1-transfected HEK293 (hTRPA1-HEK293) cells were used to evaluate the TRPA1-mediated calcium response
evoked by dacarbazine. Mechanical and cold allodynia were evaluated after acute or repeated dacarbazine administration in
naive mice or after inoculation of B16-F10 melanoma cells in C57BL/6 mice. TRPA1 involvement was investigated by using
pharmacological and genetic tools (selective antagonist or antisense oligonucleotide treatment and Trpa1 knockout mice).
Dacarbazine directly activated TRPA1 in hTRPA1-HEK293 cells and mouse DRG neurons and appears to sensitize TRPA1
indirectly by generating oxidative stress products. Moreover, dacarbazine caused mechanical and cold allodynia in naive but
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not Trpa1 knockout mice. Also, dacarbazine-induced nociception was reduced by the pharmacological TRPA1 blockade
(antagonism), antioxidants, and by ablation of TRPA1 expression. TRPA1 pharmacological blockade also reduced dacarbazine-
induced nociception in a tumor-associated pain model. Thus, dacarbazine causes nociception by TRPA1 activation, indicating
that this receptor may represent a pharmacological target for treating chemotherapy-induced pain syndrome in cancer patients
submitted to antineoplastic treatment with dacarbazine.
What’s new?
Acute and chronic pain syndromes, such as chemotherapy-induced peripheral neuropathy, are extremely common among
cancer patients, and can limit the use of chemotherapy. Several studies have indicated that the nerve receptor TRPA1 may be
involved in this kind of pain. In this study, the authors used antisense, knockout, and pharmacological methods to conclude
that the antineoplastic drug dacarbazine does induce pain signals via TRPA1 activation. This receptor may thus represent a
valuable therapeutic target for treating chemotherapy-induced pain.
Introduction
Dacarbazine is an antineoplastic drug used to treat various types of
cancers, such as Hodgkin’s lymphoma, soft-tissue sarcomas, and
some carcinomas, and it is the main chemotherapeutic agent used
in the treatment of metastatic melanomas.1,2 Due to its high meta-
static potential, melanoma is the most aggressive and deadly form
of skin cancer affecting melanocytes1,3,4 and is among the most
prevalent types of cancer, the incidence of which continues to
increase.5 Although pain is not a significant symptom of primary
melanoma, metastatic melanoma patients frequently develop
excruciating pain.6,7
In addition to cancer pain, some chemotherapeutic agents
used in the treatment of melanoma have been associated with the
development of pain.8,9 It is known that products of dacarbazine
photodegradation cause local venous pain when injected intrave-
nously, as well as inducing painful symptoms after intraperitoneal
administration in mice.10 Moreover, pain, along with other symp-
toms, such as fatigue, nausea, dyspnea and insomnia, are reported
by patients as the primary adverse effects associated with treat-
ment with dacarbazine.3
It is already well established that the use of some chemothera-
peutic agents can cause a pain syndrome characterized by acute
and chronic pain.11–13 Chemotherapy-induced chronic pain is
prevalent in 50–70% of patients who are subjected to treatment
with antineoplastic drugs.14 Its main symptoms include paresthe-
sia, mechanical and cold allodynia (pain caused by a normally
non-painful stimulus).9,15 Chemotherapy-induced pain syndrome
is the major limitation of antineoplastic treatment, because it may
require dose modification or even discontinuation, compromising
the survival and life quality of oncological patients.8 In this context,
a preclinical investigation on the pathogenesis of chemotherapy-
induced pain syndrome is necessary to identify targets for its phar-
macological intervention.8
Mechanisms have been proposed to explain this syndrome,
including an altered function of different receptors and ion chan-
nels, such as transient potential receptor ankyrin 1 (TRPA1).16,17
TRPA1 is a nonselective cation channel expressed at the nerve end-
ings and along the axons of nociceptors, where it functions as a
sensor to noxious stimuli. TRPA1 is activated by natural pungent
products (e.g., allyl isothiocyanate, allicin and cinnamaldehyde),
pollutants (e.g., acrolein and formalin) and endogenous activators
(e.g., 4-hydroxynonenal and hydrogen peroxide), leading to acute
pain. TRPA1mediates mechanical and cold allodynia after inflam-
matory conditions, cancer or nerve injury, contributing to the
development of pathological pain.16,18–20 Furthermore, oxidative
factors also contribute to the pain syndrome evoked by chemother-
apeutic agents, which may occur by oxidative stress–dependent
TRPA1 activation.13,21,22
Because TRPA1 is involved in the pathogenesis of chemother-
apy-induced pain syndrome,13,21,22 we investigated whether
dacarbazine causes cold and mechanical hypersensitivity after
acute or repeated administration in naive or in melanoma-
bearing mice and the involvement of TRPA1 in these models.
Materials and Methods
Animals
The experiments were conducted using adult male and female
wild-type C57BL/6 mice (male, 20–25 g, 5–7 weeks), litter-
mate wild-type (Trpa1+/+), and TRPA1-deficient (Trpa1−/−;
B6129P-Trpa1tm1Kykw/J) mice (25–30 g, 6–8 weeks)
backcrossed with C57BL/6 mice (Trpa1−/−) for at least 10 gen-
erations.20 The animals were maintained in a temperature-
controlled room (22  1C) under a 12-hr light/dark cycle
and with free access to food and water. All experiments were
carried out between 08:00 a.m. and 5:00 p.m., and the animals
were acclimatized to the laboratory room for at least 1 hr before
the experiments. Experiments were performed blind to the geno-
type of the animals and the drug administration. The protocols
employed in our study were approved by the Institutional Com-
mittee for Animal Care and Use of the Federal University of
Santa Maria (UFSM; protocol #7658240417/2017) and the
University of Florence (UNIFI; protocol #579/2017-PR) and
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followed the Animal Research: Reporting in vivo Experiments
(ARRIVE) guidelines.23 The number of animals and intensity of
the noxious stimuli used were the minimum necessary to dem-
onstrate the consistent effects of the treatments, in accordance
with current ethical guidelines for the investigation of experi-
mental pain in conscious animals.24
Reagents and drugs
The description of all reagents is given in the Supporting Infor-
mation. The doses of the drugs used in our study were based on
previous studies.12,13,22,25
Cellular recordings
Cell culture. Naive untransfected HEK293 cells (RRID:
CVCL_0045; American Type Culture Collection, Manassas, VA,
USA; ATCC® CRL-1573™) were cultured according to the man-
ufacturer’s instructions and transfected with cDNA for human
TRPA1 (hTRPA1-HEK293) as previously described.26 Both naive
HEK293 and transfected hTRPA1-HEK293 cells were authenti-
cated using short tandem repeat profiling within the last three
years. All the experiments were performed with mycoplasma-
free cells. For more information, please see the Supporting
Information.
Isolation of primary sensory neurons. Primary dorsal root
ganglion (DRG) neurons were isolated from C57BL/6 mice and
Trpa1+/+ and Trpa1−/− mice and cultured as previously de-
scribed.21 Detailed information are described in the Supporting
Information.
Cellular recording procedure. Cells on coated coverslips
were loaded with 5 μM Fura-2 AM-ester added directly in a
buffer solution. Changes in intracellular calcium, [Ca2+]i, were
monitored by sequential dual excitation, 340 and 380 nm
(emission 510 nm), and recorded with a dynamic image anal-
ysis system (XCellence Imaging software; Olympus Srl, Milan,
Italy).21 Detailed information are described in the Supporting
Information.
HEK293 naive, hTRPA1-HEK293 cells and DRGs neurons
were challenged with dacarbazine (0.01–300 μM) or allyl iso-
thiocyanate (AITC, 10 or 30 μM - TRPA1 agonist). Capsaicin
(1 μM—TRPV1 agonist) was used to induce a TRPV1-selective
response to identify capsaicin-sensitive neurons. The activating
peptide for human proteinase-activated receptor 2 (hPAR2-AP;
100 μM) was used to elicit a TRP-independent cellular response in
HEK293 naive and hTRPA1-HEK293 cells. KCl (40 mM) was
used to identify neurons. Some experiments were performed in the
presence of the TRPA1 selective antagonist, HC-030031 (30 or
50 μM), or its vehicle (0.3 or 0.5% DMSO) and the free radical
scavenger, phenyl N-tert-butyl nitrone (PBN, 1 mM) or its vehicle
(buffer solution). HC-030031 and PBN were applied for the dura-
tion of the experiment after a 15-min preincubation. Other experi-
ments were performed in a calcium-free buffer solution that
contained no added CaCl2 and 1.5 mM EGTA, or after exposure
to thapsigargin (1 μM) diluted in calcium-free buffer solution, to
induce intracellular calcium store depletion. Ionomycin was dis-
solved in DMSO and diluted with buffer solution or with calcium-
free buffer solution added with 5 mMCaCl2 before application.
Nociceptive parameters
Mechanical allodynia. Mechanical allodynia was evaluated
with von Frey filaments of increasing stiffness (0.02-2 g) using
the up-and-down method.13,27 The mechanical paw withdrawal
threshold was expressed in grams (g). Mechanical allodynia was
considered a decrease in the withdrawal threshold when com-
pared to the baseline values.
Cold allodynia. Cold allodynia was assessed by measuring the
acute nocifensive response to the acetone-evoked evaporative
cooling.22 A droplet (20 μl) of acetone was gently applied to the
plantar surface of themouse hind paw, and the time spent in eleva-
tion and licking of the plantar region wasmeasured for 60 sec. Ace-
tone was applied three times at a 10- to 15-min interval, and the
average of elevation/licking time was calculated. Cold allodynia
was considered as an increase in the nociceptive time observed
after exposure to acetone when compared to basal values.
Dacarbazine-induced pain model. Dacarbazine was adminis-
tered in a similar way to that previously described for paclitaxel
administration.12 For acute treatment, mice received only one
intraperitoneal (i.p.) injection of dacarbazine (1 mg/kg, i.p.).
To induce chronic pain, the animals received a repeated treatment
of dacarbazine (1 mg/kg, i.p.; 1, 3, 5 and 7 days) resulting in a
cumulative dose of 4 mg/kg. Acute (1 mg/kg, i.p.) or repeated
(1 mg/kg/4 days, i.p.) injections of paclitaxel were used as control.12
Mechanical and cold allodynia were measured before (baseline
values; B) and at 6, 24 and 48 hr after acute treatment with
dacarbazine (1 mg/kg, i.p.) or paclitaxel (1 mg/kg, i.p.) or at 7, 14,
21 and 28 days after the first injection of repeated treatment with
dacarbazine (1 mg/kg/4 days, i.p.) or paclitaxel (1 mg/kg/4 days, i.
p.). Mechanical and cold allodynia also were evaluated in
C57BL/6, Trpa1+/+ or Trpa1−/− mice after acute or repeated
dacarbazine administration.
Effect of antisense oligonucleotide for the TRPA1 receptor on
dacarbazine-induced nociception. The antisense oligonucleo-
tide for the TRPA1 receptor to evaluate the involvement of this
receptor in dacarbazine-induced nociception was also used. The
animals were treated intrathecally (5 μl/site) with antisense oli-
gonucleotide for TRPA1 (AS TRPA1 ODN, 30 μg) or with mis-
match oligonucleotide (MM TRPA1 ODN; 30 μg) three times
a day for three consecutive days (Days 11, 12 and 13) after the
first dacarbazine administration.20 Then, mechanical and cold
allodynia were evaluated on the 14th day after the first dacarbazine
(1 mg/kg/4 days, i.p.) administration.
To confirm that intrathecal treatment with the antisense oli-
gonucleotide for TRPA1 reduced TRPA1 mRNA expression, a
real-time quantitative PCR was performed. For more informa-
tion, check the Supporting Information.
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TRPA1 receptor protein expression. Expression of the TRPA1
receptor protein was assessed by western blotting in sciatic
nerve samples after the vehicle (10 ml/kg, i.p.) or dacarbazine
(1 mg/kg/4 days, i.p.) administration.20,28 Detailed informa-
tion are described in the Supporting Information.
Effect of TRPA1 antagonist and antioxidant administration on
dacarbazine-induced nociception. Animals were orally treated
with vehicle (10 ml/kg) or TRPA1 antagonists HC-030031
(300 mg/kg) or A-967079 (60 mg/kg) on the 14th day after the
first dacarbazine (1 mg/kg/4 days, i.p.) administration. The anti-
nociceptive potential of antioxidant compounds, such as NAC
(200 mg/kg, i.p.) and α-lipoic acid (100 mg/kg, p.o.), was also
evaluated in the dacarbazine-induced nociception model. First, on
Day 14 after the first dacarbazine administration, the mechanical
threshold (time 0) or nociception time (time 0) of mice were eval-
uated. Next, mice received treatment with TRPA1 antagonists or
antioxidants, and the mechanical threshold and the nociception
time were again evaluated from 1 to 3 hr after treatments.
Dacarbazine-induced nociception in a tumor-associated pain
model. We also evaluated the effect of TRPA1 receptor antago-
nists on the dacarbazine-induced hypersensitivity in animals with
melanoma. For tumor inoculation, 20 μl of B16-F10 melanoma
cells (2 x 105 cells suspended in PBS) were injected subcutane-
ously into the plantar region of the right hind paw.7,20 On the
fifth day after tumor inoculation, the animals received vehicle
(10 ml/kg, i.p.), dacarbazine (1 mg/kg/4 days, i.p.) or paclitaxel
(1 mg/kg/4 days, i.p.). HC-030031 (300 mg/kg, p.o.—a TRPA1
antagonist) and NAC (200 mg/kg, i.p.—an antioxidant) were then
administrated at Day 7 after the first administration of vehicle,
dacarbazine or paclitaxel. Another group of animals received only
dacarbazine (1 mg/kg/4 days, i.p.) or paclitaxel (1 mg/kg/4 days,
i.p.) administrations as control. The mechanical and cold allodynia
were then evaluated 1, 2 and 3 hr after treatments.
Measurement of H2O2 released from cells. H2O2 was deter-
mined in hTRPA1-HEK293 or naive untransfected HEK293
cells. For more information, see Supporting Information.
Measurement of H2O2 levels in tissue. The H2O2 levels were
determined in sciatic nerve tissue collected on day 14 after the first
vehicle (10 ml/kg, i.p.) or dacarbazine (1 mg/kg/4 days, i.p.) admin-
istration.29 Formore information, see Supporting Information.
Cell viability measurement by 3(4-5-dimethyl)-2-5-diphenyl
tetrazolium bromide (MTT) salt reduction assay
The possible cytotoxic effect of HC-030031 (TRPA1 antago-
nist), dacarbazine and paclitaxel was evaluated through cell
viability assay by MTT.30 Detailed information are described
in the Supporting Information.
Statistical analysis
Results were expressed as the mean and standard error of the
mean (SEM). Statistical analyses were performed using Graph
Pad Prism 6.0 software. The significance of difference among
groups was evaluated with the Mann–Whitney test, one-way or
two-way analysis of variance (ANOVA) followed by Tukey’s post
hoc test or Bonferroni post hoc test. To meet parametric assump-
tions, the data of mechanical threshold were log transformed
before analyses. p values less than 0.05 were considered signifi-
cant. Proportional Venn diagram was drawn using BioVinci 1.1.5
software (https://vinci.bioturing.com).
Data availability
Data will be made available upon reasonable request.
Results
Dacarbazine selectively activates the human TRPA1 channel
and excites TRPA1 in rodent sensory neurons
Dacarbazine evoked a concentration-dependent calcium response
in hTRPA1-HEK293 cells (EC50 23  0.5 μM) (Fig. 1a). The cal-
cium response evoked by dacarbazine (30 μM) was abolished by
TRPA1 antagonist HC-030031 which, as expected, also abolished
the calcium response to TRPA1 selective agonist AITC and failed to
attenuate calcium responses evoked by the PAR2 agonist, SLIGKV-
NH2, thus indicating selectivity (Fig. 1a). Dacarbazine, as well as the
selective TRPA1 agonist AITC, did not evoke a calcium response in
naiveHEK293 cells that responded to hPAR2-AP (Fig. 1b).
To determine if the calcium signals originate from intracellular
stores, hTRPA1-HEK293 cells were preincubated in the absence
of extracellular calcium, which completely abolished dacarbazine-
evoked calcium responses (Fig. 1c), thus suggesting that the
elevation in intracellular calcium is the result of TRPA1-mediated
calcium influx. Furthermore, hTRPA1-HEK293 cells were
preincubated with the intracellular calcium store depletion
agent, thapsigargin (TG, 1 μM), in the absence of extracellular cal-
cium, which again completely abolished dacarbazine calcium
responses, confirming previous observations (Fig. 1c). In addition,
the exposure of cells to the free radical scavenger phenyl N-tert-
butyl nitrone (PBN) indicated that TRPA1 is directly gated by
dacarbazine and not by ROS production (Fig. 1c). PBN also did
not affect the calcium response to the PAR2 agonist (Fig. 1c).
Exposure of cultured mouse DRG neurons to dacarbazine
evoked a concentration-dependent calcium response in a subset of
cells, identified as neurons due to their ability to respond to KCl,
and as nociceptors for their ability to respond to capsaicin (TRPV1
agonist) and AITC (TRPA1 agonist) (Figs. 1d and 1e). In mouse
DRG neurons, the maximum calcium response to dacarbazine was
24  2% of ionomycin, and EC50 was 16  0.5 μM (Fig. 1d). Cal-
cium responses elicited by dacarbazine or AITC were blocked by
exposure to TRPA1 antagonist HC-030031, which did not affect
the response evoked by capsaicin and KCl, indicating selectivity
(Fig. 1d). Notably, dacarbazine and AITC produced calcium
responses in capsaicin-sensitive DRG neurons isolated from
Trpa1+/+ mice, an effect that was absent in neurons obtained
from Trpa1−/− mice (Fig. 1e). The calcium responses to capsai-
cin and KCl were unchanged in both mouse strains (Fig. 1e).
The percentage of dacarbazine-responding and AITC-responding
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Figure 1. Dacarbazine selectively targets human and rodent TRPA1. (a) Concentration-response curve, typical traces and cumulative data of the
calcium responses evoked by dacarbazine and AITC (TRPA1 agonist) in hTRPA1 HEK293 cells exposed to the TRPA1 selective antagonist, HC-030031
(HC, 30 μM) or its vehicle (−). (b) Typical trace and cumulative data of calcium responses evoked by dacarbazine and AITC in naive HEK293 cells that
responded to hPAR2-AP (100 μM). Veh is the vehicle of dacarbazine, dash (−) indicates the vehicle of HC03. Data are mean + SEM of n > 20 cells
from four independent experiments. #p < 0.05 when compared to the vehicle group; *p < 0.05 when compared to the dacarbazine or AITC group; one-
way ANOVA followed by Bonferroni post hoc test. (c) Typical traces and cumulative data of calcium responses evoked by dacarbazine in the absence
of extracellular calcium (calcium free) or in the presence of intracellular calcium store depletion agent, thapsigargin (TG, 1 μM) and in the presence of
the free radical scavenger phenyl N-tert-butyl nitrone (PBN, 1 mM). (d) Concentration–response curve, typical traces and cumulative data of calcium
responses evoked by dacarbazine, AITC, capsaicin (CPS; TRPV1 agonist) and KCl in mouse DRG neurons exposed to HC (50 μM), or its vehicle (−).
(e) Typical traces and cumulative data of calcium responses evoked by dacarbazine, AITC, CPS and KCl in DRG neurons isolated from Trpa1+/+ and
Trpa1−/−mice. Veh is the vehicle of dacarbazine. (f) Venn diagram showing proportionally the percentage of dacarbazine and AITC-responding
neurons out of the KCl-responding neurons. Data are mean + SEM of n > 20 cells from four independent. *p < 0.05 when compared to the veh;
§p < 0.05 when compared to the dacarbazine or AITC; one-way ANOVA followed by Bonferroni post hoc test.
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neurons out of the KCl-responding neurons was similar in mouse
DRG. In 100 neurons (KCl+) analyzed, 81%, 59% and 49%neurons
showed responses to capsaicin, AITC and dacarbazine, respectively
(Fig. 1f ).
Dacarbazine administration induces mechanical and cold
allodynia in mice
Dacarbazine or paclitaxel caused mechanical allodynia in C57BL/6
mice, characterized by the reduction of the paw withdrawal thresh-
old in response to von Frey filaments, and induced cold allodynia
resulting in an increased nociception time in the acetone test when
compared to the vehicle. Mechanical allodynia was observed 48 hr
after dacarbazine administration (46  7% of threshold reduction)
and at 24 and 48 hr after paclitaxel administration (71  5% of
threshold reduction at 24 hr). Cold allodynia was observed at
24 and 48 hr after dacarbazine and paclitaxel acute administrations
(71  21% and 100% of increased nociception time at 48 hr,
respectively; Figs. 2a and 2b).
Repeated administration of dacarbazine, but not vehicle, also
induced mechanical and cold allodynia in mice at 7, 14 and
21 days after the first administration, characterizing the develop-
ment of pain hypersensitivity. The maximum reduction of the
mechanical threshold observed was 60  3% at Day 14, and the
nociception time increase in the cold allodynia test was 100% at
all days. The paclitaxel repeated administration caused mechani-
cal and cold allodynia at 7, 14, 21 and 28 days after its first
administration with a maximum reduction of the mechanical
threshold of 73  2% at day 7 and increased the nociception time
in the cold allodynia test by 100% at all days (Figs. 2c and 2d).
TRPA1-deficient mice and antisense oligonucleotide for the
TRPA1 receptor reduces dacarbazine-induced nociception
Dacarbazine acute administration inducedmechanical allodynia in
Trpa1+/+ mice from 24 to 48 hr and cold allodynia at 48 hr after
administration, when compared to the vehicle group. Repeated
administration of dacarbazine also induced mechanical and cold
Figure 2. Dacarbazine and paclitaxel acute or repeated administration cause mechanical allodynia (a, c) and cold allodynia (b, d) in mice.
The nociceptive tests were evaluated at 6, 24 and 48 hr after vehicle (10 ml/kg, i.p.), dacarbazine (1 mg/kg, i.p.) or paclitaxel (1 mg/kg, i.p.)
acute administration (a, b); or at 7, 14, 21 and 28 days after first vehicle (10 ml/kg, i.p.), dacarbazine (1 mg/kg/4 days, i.p.) or paclitaxel
(1 mg/kg/4 days, i.p.) repeated administration (c, d). (B) denotes baseline mechanical threshold/nociception time before administration.
Data are expressed as the mean + SEM (n = 8). *p < 0.05, **p < 0.01, ***p < 0.001, when compared to the vehicle group (two-way ANOVA
followed by Tukey’s post hoc test).
6 Hypersensitivity induced by dacarbazine
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Figure 3. Gene deletion and antisense oligonucleotide for TRPA1 reduces dacarbazine-induced nociception in mice. The nociceptive tests
were evaluated in Trpa1+/+ and Trpa1−/− at 6, 24 and 48 hr after vehicle (10 ml/kg, i.p.) or dacarbazine (1 mg/kg, i.p.) acute administration
(a, b); or at 7 and 14 days after the first vehicle (10 ml/kg, i.p.) or dacarbazine (1 mg/kg/4 days, i.p.) repeated administration (c, d).
Mechanical allodynia (e) and cold allodynia (f ) were evaluated after injections of antisense oligonucleotide (AS ODN) for TRPA1 or control
oligonucleotide (mismatch, MM ODN) on Day 14 after the first dacarbazine (1 mg/kg/4 days, i.p.) repeated administration. (B) denotes the
baseline mechanical threshold/nociception time before dacarbazine administration. Data are expressed as mean + SEM (n = 8). #p < 0.05,
##p < 0.01; ###p < 0.001 when compared to the wild-type mice/vehicle group or when compared to the nonsense group; **p < 0.01;
***p < 0.001 when compared to the wild-type mice/dacarbazine group or when compared to basal values (two-way ANOVA followed by
Tukey’s post hoc test).
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allodynia from Days 7–14 after the first administration when com-
pared to the vehicle group (Fig. 3). Trpa1−/− did not develop
mechanical and cold allodynia after dacarbazine acute administra-
tion when compared to Trpa1+/+ mice. Maximal inhibitions were
60  10% and 92  4% to mechanical and cold allodynia, respec-
tively, at 48 hr after dacarbazine administration (Figs. 3a and 3b).
Trpa1−/− did not develop mechanical and cold allodynia induced
by dacarbazine repeated administration. Maximal inhibitions were
95  5% and 71  1% to mechanical and cold allodynia, respec-
tively, on Day 14 after the first dacarbazine administration (Figs. 3c
and 3d).
Because the maximum nociceptive effect of dacarbazine
was observed on Day 14 after its first administration, and
TRPA1-deficient mice prevented the dacarbazine-induced
chronic nociception, we chose Day 14 to evaluate the effect of
the antisense oligonucleotide and TRPA1 antagonists in
dacarbazine-induced pain hypersensitivity.
Intrathecal injection of TRPA1 AS ODN, which signifi-
cantly reduced TRPA1 mRNA expression in L5-L6 DRGs
(value of mRNA expression relative to β-actin TRPA1
MM ODN 1.24 x 10−7  0.25 x 10−7 and TRPA1 AS ODN
0.68 × 10−7  0.11 × 10−7; n = 4 mice), caused an anti-allodynic
effect on the dacarbazine-induced chronic nociception. TRPA1 AS
ODN reduced dacarbazine-inducedmechanical and cold allodynia
on Day 14 after the first dacarbazine administration with maximal
inhibitions of 23  5% and 57  9%, respectively. However, the
control oligonucleotide injection (TRPA1 MMODN) did not alter
the dacarbazine-induced mechanical and cold allodynia (Figs. 3e
Figure 4. TRPA1 antagonists (HC-030031 and A-967079) and antioxidants (n-acetylcysteine—NAC and α-lipoic acid) cause anti-
allodynic effect on the dacarbazine-induced nociception in mice. Time–response curves for mechanical allodynia (a) and cold
allodynia (b) after treatment with vehicle (10 ml/kg, p.o.), HC-030031 (300 mg/kg, p.o.) or A-967079 (60 mg/kg, p.o.) in animals that
received dacarbazine (1 mg/kg/4 days, i.p.) repeated administrations. Time–response curves for mechanical allodynia (c) and cold
allodynia (d) after treatment with vehicle (10 ml/kg, p.o.), NAC (200 mg/kg, i.p.) or α-lipoic acid (100 mg/kg, p.o.) in animals that
received dacarbazine (1 mg/kg/4 days, i.p.) administrations. (B) denotes the baseline mechanical threshold/nociception time before
dacarbazine administration, while 0 indicates the basal at 14 days after first dacarbazine administration. Data are expressed as the
mean + SEM (n = 8). #p < 0.05; ##p < 0.01; ###p < 0.001, when compared to the baseline (B) (One-way ANOVA followed by Tukey’s post
hoc test). *p < 0.05, **p < 0.01, ***p < 0.001, when compared to the vehicle group (two-way ANOVA followed by Tukey’s post
hoc test).
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and 3f). Moreover, dacarbazine did not alter the TRPA1 expres-
sion in the sciatic nerve at Day 14 after its first administration when
compared to the vehicle group (data not shown).
Selective TRPA1 receptor antagonists and antioxidants
reduce dacarbazine-induced chronic nociception
Oral administration of TRPA1 antagonists HC-030031
(300 mg/kg) or A-967079 (60 mg/kg) promoted anti-allodynic
effects on the dacarbazine-induced chronic nociception when com-
pared to the vehicle group. HC-030031 reduced the dacarbazine-
induced mechanical and cold allodynia at 1 and 2 hr or at 2 hr
after its administration, respectively. Maximal inhibitions were
48  12% and 100% for mechanical and cold allodynia at 1 and
2 hr, respectively. A-967079 also reduced the dacarbazine-induced
mechanical and cold allodynia at 1 and 2 hr after its administration,
with maximal inhibitions of 32  5% and 78  10%, respectively,
observed at 1 hr after treatment (Figs. 4a and 4b).
Antioxidants NAC (200 mg/kg, i.p.) or α-lipoic acid
(100 mg/kg, p.o.) caused an anti-allodynic effect on dacarbazine-
induced chronic nociception when compared to the vehicle. NAC
reduced dacarbazine-induced mechanical and cold allodynia at
1 and 2 hr after its administration. Maximal inhibitions were
27  7% and 71  8% for mechanical and cold allodynia at
2 and 1 hr, respectively. However, α-lipoic acid was able to
Figure 5. TRPA1 antagonist (HC-030031) and antioxidant (n-acetylcysteine, NAC) caused anti-allodynic effect on the dacarbazine- or
paclitaxel-induced nociception in a tumor-associated pain model in mice. Time-response curves for mechanical allodynia (a, c) and cold
allodynia (b, d) after treatment with vehicle (10 ml/kg, p.o.), HC-030031 (300 mg/kg, p.o.) or NAC (200 mg/kg, i.p.) at 12 days after tumor
inoculation and at 7 days after first dacarbazine (1 mg/kg/4 days, i.p., a, b) or paclitaxel (1 mg/kg/4 days, i.p., c, d) repeated administration.
(B) denotes the baseline mechanical threshold/nociception time before induction of the model, while 0 indicates the basal after induction of
the model. Data are expressed as the mean + SEM (n = 6–9). #p < 0.05; ##p < 0.01; ###p < 0.001, when compared to the baseline (B) (One-way
ANOVA followed by Tukey’s post hoc test). *p < 0.05, **p < 0.01, ***p < 0.001, when compared to the tumor plus dacarbazine or plus
paclitaxel-treated with vehicle group (two-way ANOVA followed by Tukey’s post hoc test).
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reduce just the dacarbazine-induced mechanical allodynia at
2 hr after its administration with a maximum inhibition of
23  7% (Figs. 4c and 4d).
We also observed that dacarbazine increased H2O2 levels
(61  5%) in the sciatic nerve at Day 14 of its first administration
when compared to the vehicle group. The values observed were
19  3 and 31  5 nmol of H2O2/mg protein for the vehicle or
dacarbazine group, respectively (p < 0.05 sec Mann–Whitney test).
In cellular systems, prolonged exposure to dacarbazine resulted in
H2O2 production via a TRPA1-dependentmechanism.Dacarbazine
(10, 30 and 100 μM) increased the H2O2 levels by 2 (to 10 and
30 μM) or 3.2 times (100 μM) in hTRPA1-HEK293 cells when
compared to naive untransfected HEK293 cells (data not shown;
p < 0.05 one-way ANOVA followed by Bonferroni post hoc test).
TRPA1 antagonist or an antioxidant cause antinociceptive
effects on dacarbazine- or paclitaxel-induced nociception in
a tumor-associated cancer pain model
The tumor, or dacarbazine and paclitaxel repeated treatment, as
well as tumor plus dacarbazine or plus paclitaxel repeated admin-
istration, induced mechanical and cold allodynia when compared
to its baseline threshold (B) (Fig. 5). TRPA1 antagonist HC-
030031 (300 mg/kg, p.o.) or the antioxidant NAC (200 mg/kg,
i.p.) promoted anti-allodynic effects on the dacarbazine- or
paclitaxel-induced nociception in a tumor-associated painmodel.
HC-030031 and NAC reduced the dacarbazine-inducedmechan-
ical allodynia at 1 and 2 hr after its administration with maximal
inhibitions of 24  1% and 22  4% at 2 hr, respectively. HC-
030031 also reduced the dacarbazine-induced cold allodynia at
1 and 2 hr after its administration with maximal inhibition of
55  9% at 2 hr. NAC caused an anti-allodynic effect on cold
allodynia only at 2 hr after its administration with maximal inhi-
bition of 38  10% (Figs. 5a and 5b).
HC-030031 and NAC also promoted anti-allodynic effects
in animals with tumors that received repeated paclitaxel
administrations. The anti-allodynic effect of HC-030031 on
mechanical and cold allodynia occurred at 1 and 2 hr after its
administration with maximal inhibition of 36  7% and
62  9% at 1 hr, respectively. NAC presented anti-allodynic
effects only on the mechanical allodynia with a maximal inhi-
bition of 23  4% at 2 hr after its administration (Figs. 5c
and 5d).
On the other hand, dacarbazine and paclitaxel did not
reduce cell growth in vivo (data not shown) in the time evalu-
ated, because the goal was to show the nociception induced by
chemotherapy plus tumor inoculation. A longer time than
14 days after tumor inoculation, it would be difficult to mea-
sure the mechanical and cold allodynia because the paw edema
would be large, therefore making it impossible to measure
nociception.
Figure 6. B16-F10 cell viability assessed in vitro by MTT assay. (a) TRPA1 antagonist HC-03003 (1–100 μM), (b) paclitaxel (PAC, 1–100 μM),
(c) dacarbazine (DTIC, 100–10,000 μM). (d) HC-030031 (100 μM) associated with PAC (100 μM) or DTIC (10,000 μM). Control samples denote
only DMEM culture medium. Control plus DMSO samples indicate DMEM culture medium plus DMSO 0.05%. ***p < 0.001, when compared to
control samples (two-way ANOVA followed by Bonferroni’s post hoc test).
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HC-030031 did not alter the paclitaxel or dacarbazine
cytotoxic action on B16-F10 melanoma cells
The toxicity development of TRPA1 antagonist HC-030031 was
assessed in vitro, using B16-F10 melanoma cell lines throughMTT
assay, which revealed that HC-030031 did not alter cell viability,
regardless of the concentrations tested in comparison with the con-
trol group (Fig. 6a). On the contrary, B16-F10 incubation with
paclitaxel showed a cell viability decrease in a concentration
dependent-manner at paclitaxel highest concentration (100 μM),
with an inhibition percentage of 73  6% after 24 hr of incubation
when compared to control samples (Fig. 6b). Also, dacarbazine
reduced cell viability to 3,000 and 10,000 μM, with an inhibition
percentage of 62  2% after 24 hr of incubation (Fig. 6c).
In the second set of experiments, we evaluated whether the
association of HC-030031 might interfere with the paclitaxel or
dacarbazine chemotherapeutic effect. MTT assay showed that HC-
030031 in the highest concentration (100 μM), when associated
with paclitaxel or dacarbazine highest concentrations (100 or
10,000 μM), did not interfere with the chemotherapeutic action of
these drugs (Fig. 6d). The B16-F10 incubation with paclitaxel, pac-
litaxel plus HC-030031, dacarbazine and dacarbazine plus HC-
030031 showed an inhibition percentage of 54  1, 56  1,
76  1 and 77  1%, respectively, after 24 hr of incubation, com-
pared to control samples (Fig. 6d).
Discussion
Antineoplastic therapy has been associated with the development
of pain syndrome, which puts limits to its use and compromises
the patient’s quality of life.8 Among these therapies, dacarbazine is
reported to cause pain symptoms in animal models10 and oncolog-
ical patients.3,31 In the present study, dacarbazine stimulated
TRPA1 in culturedmouse DRG neurons and in hTRPA1-HEK293
cells, effects that were abolished by a TRPA1 antagonist. Moreover,
we demonstrated that dacarbazine caused mechanical and cold
allodynia in mice by TRPA1 activation and sensitization, which
was reduced by TRPA1 pharmacological blockade, antioxidants
and by TRPA1 gene deletion or silencing. Thus, our results indicate
that the acute and chronic nociception caused by dacarbazine
occurs due to the TRPA1 activation or sensitization.
It is known that mechanical and cold allodynia are among
the predominant symptoms of chemotherapy-induced pain syn-
drome.9 Here, we observed that acute or repeated dacarbazine
administration caused mechanical and cold allodynia starting at
24 hr after acute administration to Day 21 after repeated admin-
istration, thus characterizing the chronic pain development. Such
effects of dacarbazine were similar to those of paclitaxel, whose
pain syndrome is already well described.9,12,32 Our findings are
in accordance with preclinical and clinical data showing that che-
motherapeutic agents promote acute pain starting early from
1 to 2 days after administration, and persistent pain, which is
more prominent if preceded by acute pain.8,11,12,16 Thus, we are
showing for the first time that chemotherapeutic dacarbazine
induces pain syndrome in mice.
Several mechanisms have been proposed to explain
chemotherapy-induced pain syndrome.8,9 TRP channels have been
the subject of intense investigation, mainly due to their prevalent
localization in a subset of nociceptive sensory neurons.16,33 Among
them, TRPA1 channel is an essential pain transducer of noxious
stimulus (mechanical or thermal), playing a critical role in the per-
ception and transmission of acute and persistent pain conditions,
such as inflammation, cancer and neuropathies.16,19,20,34 Many
studies reported TRPA1 involvement in chemotherapy-induced
pain syndrome, including the chemotherapeutic agents, oxaliplatin
and cisplatin, bortezomib and paclitaxel.13,21,22
Different from some chemotherapeutic agents that do not
appear to directly stimulate TRPA1,13,21,22 we showed that
dacarbazine selectively activates TRPA1 when evaluated in
human TRPA1-HEK293 cells and cultured mouse DRG neu-
rons, a response abolished by TRPA1 antagonist HC-030031.
The dacarbazine action is like that observed for aromatase
inhibitors, exemestane, letrozole and anastrozole; and the aro-
matase substrate androstenedione,35,36 which were able to
directly activate the TRPA1 causing pain conditions. This evi-
dence is derived from the observation that dacarbazine evoked
calcium response in hTRPA1-HEK293 cells but not in naive
cells, in which it was abolished by the selective TRPA1 antag-
onist HC-030031. The increase of intracellular calcium evoked
by dacarbazine resulted from TRPA1-mediated calcium influx
and not from calcium release of intracellular stores. Moreover,
exposure to a free radical scavenger (PBN) did not affect the
response to calcium evoked by dacarbazine, in agreement with pre-
vious reports for the selective TRPA1 agonist AITC.19 Likewise,
mouse DRG neurons, which constitutively express the channel,
when exposed to dacarbazine evoked calcium response in a subset
of cells, identified as nociceptors by their ability to respond to cap-
saicin (TRPV1 agonist) and AITC (TRPA1 agonist). Moreover,
HC-030031 blocked calcium responses elicited by dacarbazine in
DRG neurons and neurons isolated fromTrpa1−/−mice.
In vivo data recapitulate the in vitro findings. Administration of
dacarbazine in mice induced mechanical and cold allodynia. To
confirm the involvement of TRPA1 in dacarbazine-induced pain
syndrome, we tested TRPA1 deficiency or silencing. As reported in
other chemotherapy-induced pain models,13,21 TRPA1-deficient
mice prevented the development of mechanical and cold allodynia
induced by dacarbazine. Likewise, TRPA1 silencing attenuated the
dacarbazine-induced nociceptive responses, corroborating with
previous data19,20 that reported a selective reduction of nociceptive
signals in neuropathic or cancer pain models after TRPA1 silenc-
ing. These observations indicate that the TRPA1 is necessary to
trigger the nociceptive responses evoked by dacarbazine. On the
other hand, dacarbazine did not affect TRPA1 expression in the
sciatic nerve of the mice, confirming previous findings from our
research group on the bortezomib chemotherapeutic.13
In addition to the genetic manipulation, we observed that
the pharmacological blockade of TRPA1 using the antagonists
HC-030031 and A-967079 reversed the dacarbazine-induced
mechanical and cold allodynia. The ability of such antagonists
Brusco et al. 11
Int. J. Cancer: 00, 00–00 (2019) © 2019 UICC
C
an
ce
r
T
he
ra
py
an
d
P
re
ve
n
ti
on
to reduce nociceptive parameters induced by chemotherapeutic
agents as oxaliplatin, paclitaxel and bortezomib was previously
reported.16 In contrast to the data observed in TRPA1-deficient
mice, in which dacarbazine did not induce painful hypersensitivity,
the pharmacological TRPA1 blockade produced a transient rever-
sal of nociceptive parameters when hypersensitivity was already
established, corroborating with previous findings using different
chemotherapy agents, such as oxaliplatin and bortezomib.13,21 This
transient antinociceptive effect has been associated with the phar-
macokinetic properties of both TRPA1 antagonists.37,38
The temporary effect of the antagonists also suggests that other
factors produced by dacarbazine may be collaborating to sustain
the nociception induced by it. Such factors could be associated with
oxidative mechanisms because we observed that dacarbazine
increased the H2O2 levels in hTRPA1-HEK293 cells and in the sci-
atic nerve of animals. Indeed, the dacarbazine cytotoxicity effect
was previously associated with reactive species generation, such as
H2O2 and superoxide anion.
39 We also observed that the antioxi-
dants, NAC and α-lipoic acid reduced the dacarbazine-induced
mechanical and cold allodynia. Similar to our findings, antioxidant
substances have been reported to reduce painful hypersensitivity in
animal models13,22 and patients with the chemotherapy-induced
pain syndrome.40,41
Our data expand on previous findings of the oxidative role in
pain syndrome evoked by chemotherapeutic agents, which seem
to induce mechanical and cold allodynia by oxidative stress-
dependent TRPA1 activation.16 TRPA1 has been referred to as a
significant oxidant sensor, because many by-products of oxidative
stress, such as reactive oxygen and nitrogen species, including
H2O2, selectively activate this channel.
42,43 In our study,
dacarbazine increased both tissue and cellular H2O2 levels.
Thus, we hypothesized that besides the direct TRPA1 activation
and sensitization by dacarbazine, as observed by the evoked
response to calcium, this chemotherapy also indirectly sen-
sitizes/activates TRPA1 in sensory neurons by generating oxida-
tive stress products.
Besides the involvement of TRPA1 in chemotherapy-induced
pain, a recent study showed its involvement in melanoma-induced
cancer pain.20 Because dacarbazine is the main chemotherapeutic
agent used to treat metastatic melanoma,1,2,44 we performed a can-
cer pain protocol by associating the B16-F10 melanoma tumor cell
inoculation with dacarbazine administration. The association of
tumor cells and dacarbazine did not produce additional nocicep-
tive behavior because maximum nociception was achieved after a
single dacarbazine administration. However, dacarbazine treat-
ment in melanoma cells-injected mice caused mechanical and cold
allodynia in mice which was reversed by the TRPA1 antagonist
HC-030031 and by the antioxidant NAC. Like some chemothera-
peutic agents,13,22 melanoma tumor cells may also increase oxida-
tive stress products which activate TRPA1.20,42 Moreover, both
TRPA1 antagonists and antioxidants have attenuated nociceptive
responses in amelanoma cancer painmodel.20
Considering that it is difficult to evaluate if the patient’s
pain is caused by a tumor or by the chemotherapeutic treat-
ment, our results can reinforce the findings of Antoniazzi
et al. (2018) on the TRPA1 role in the painful hypersensitivity
followed by the melanoma cell inoculation. This is because we
verified that TRPA1 antagonists and antioxidants could block
the pain caused by chemotherapy, as well as the dacarbazine-
and paclitaxel-induced nociception in a tumor-associated pain
model in mice. Similar to dacarbazine, paclitaxel is also used
to treat metastatic melanoma45,46 and has been reported to
cause pain syndrome by the TRPA1 activation.22 Thus, the
TRPA1 pharmacological blockade is also expected to reduce
paclitaxel-induced nociception in melanoma-inoculated mice.
Despite intensive efforts, chemotherapy-induced pain syn-
drome remains the major limitation of antineoplastic therapy, and
no treatment is available, making it necessary to search for phar-
macological intervention targets.8 Extending previous findings on
the involvement of TRPA1 in chemotherapy-induced pain,16 our
results showed that dacarbazine causes acute and chronic pain by
TRPA1 activation and sensitization. It is important to note that
TRPA1 antagonists have recently advanced into clinical studies for
the treatment of neuropathic pain. In human Phase 2 clinical trials,
the antagonist GRC 17536 was effective in reducing the pain of
patients with diabetic neuropathy without presenting notable
adverse effects.47 Therefore, because blocking TRPA1 also reduced
chemotherapy-induced nociception in the tumor-associated pain
model, our results reinforce previous studies,16 indicating that
TRPA1may represent a unique pharmacological target for treating
cancer patients who, while undergoing chemotherapeutic treat-
ment, develop chemotherapy-induced pain syndrome.
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